The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine
Authors:
Open Access
- 7 August 2009
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (2) , 238-242
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Extrapyramidal side‐effects induced by antipsychotic agents are treated with dose reduction, switching of antipsychotic medication or the addition of anticholinergic antiparkinson drugs. WHAT THIS STUDY ADDS • The use of anticholinergic antiparkinson drugs appears to be superfluous in a large number of patients.AIMS: Extrapyramidal side‐effects induced by antipsychotic drugs are treated with dose reduction or substitution with another antipsychotic drug or by the addition of anticholinergic antiparkinson agents. The withdrawal of orphenadrine from the Norwegian market provided a possibility to investigate to what degree these alternative measures were taken in clinical practice.METHODS: Data were drawn from the Norwegian Prescription Database on the sales of antipsychotics and one of the two anticholinergic antiparkinson agents marketed in 2004, orphenadrine and biperiden, to a total of 39 758 outpatients. The patients were reinvestigated in 2007. The consequences of the withdrawal of orphenadrine from the Norwegian market in 2005 regarding dosing, switching and cessation of antipsychotics and use of anticholinergics were assessed for orphenadrine users compared with biperiden users.RESULTS: Of the patients originally using orphenadrine, 28.4% stopped using the drug without reducing the antipsychotic dose or replacing orphenadrine with another anticholinergic agent. The corresponding number for biperiden users was 19.3%. Only 11.8% of patients switched to another antipsychotic drug, but they used significantly lower antipsychotic doses than those who stayed on the same drug.CONCLUSION: The use of anticholinergic antiparkinson agents could be seen as superfluous for at least one‐third of patients.Keywords
This publication has 12 references indexed in Scilit:
- The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological studyBritish Journal of Clinical Pharmacology, 2009
- Effect of warnings in a medical journal on the use of orphenadrineJournal of Evaluation in Clinical Practice, 2008
- Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adultsCanadian Medical Association Journal, 2008
- Anticholinergic use in hospitalised schizophrenic patients in BelgiumPsychiatry Research, 2007
- Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a ComparatorPsychiatric Services, 2005
- Psychotic Depression and MortalityAmerican Journal of Psychiatry, 2003
- [Mortality in schizophrenic patients. 3 years follow-up of a cohort].1999
- Improving drug use: a case study of events which led to changes in use of flucloxacillin in AustraliaSocial Science & Medicine, 1999
- Fatal toxicity of drugs used in the treatment of psychotic illnessesThe British Journal of Psychiatry, 1998
- Prophylactic Use of Anticholinergics in Patients on Long-Term Neuroleptic TreatmentThe British Journal of Psychiatry, 1990